Xenon Pharmaceuticals (XENE) Total Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has 4 years of Total Debt data on file, last reported at $15.7 million in Q1 2020.

• Total Debt for Q1 2020 came in at $15.7 million, up 3.55% year-over-year; the trailing twelve-month figure through Mar 2020 was $15.7 million (up 3.55% YoY), and the FY2019 annual result was $15.5 million, up 3.5% from the prior year.
• Total Debt rose to $15.7 million in Q1 2020 per XENE's latest filing, from $15.5 million in the prior quarter.
• Over five years, Total Debt peaked at $15.7 million in Q1 2020 and troughed at $6.8 million in Q4 2017.
• A 4-year average of $13.2 million and a median of $15.1 million in 2018 frame the typical range for Total Debt.
• The sharpest annual moves came in 2018 and 2019: Total Debt surged 120.66% in 2018, then increased 3.47% in 2019.
• A 4-year view of Total Debt shows it stood at $6.8 million in 2017, then surged by 120.66% to $15.0 million in 2018, then gained by 3.5% to $15.5 million in 2019, then increased by 0.88% to $15.7 million in 2020.
• Business Quant data shows XENE's Total Debt at $15.7 million in Q1 2020, $15.5 million in Q4 2019, and $15.4 million in Q3 2019.